Literature DB >> 21301899

The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group.

Akihiko Takeuchi1, Hiroyuki Tsuchiya, Xiaohui Niu, Takafumi Ueda, Dae-Geun Jeon, Edward H M Wang, Apichat Asavamongkolkul, Katsuyuki Kusuzaki, Kenshi Sakayama, Yong-Koo Kang.   

Abstract

BACKGROUND: Giant-cell tumor (GCT) of bone is a common primary benign tumor with high local recurrence and potential distant metastasis or malignant transformation. We have investigated the clinical behavior of recurrent GCT of bone in the extremities.
METHODS: We retrospectively reviewed 110 patients with recurrent GCTs of bone in the extremities treated by the Eastern Asian Musculoskeletal Oncology Group. The factors that affected the number of recurrences and distant metastasis were analyzed.
RESULTS: The median interval between initial surgery and the first recurrence of GCT was 16 months (2-180 months). All patients received additional surgery for first recurrence. Twenty-five patients had a second recurrence and 6 patients had a third recurrence. The mean interval between the initial surgery and the first recurrence correlated with the eventual number of recurrences-14.1 months for the repeated recurrence groups (two and three recurrences) and 28.3 months for the single recurrence group (p = 0.016). Campanacci grade did not correlate with repeated recurrence (p = 0. 446). The venue of the initial surgery did not correlate with recurrence but did affect preservation of the adjacent joint (chi-squared test; p = 0.046). Campanacci grade II and III also correlated with sacrifice of the adjacent joint (p = 0.020). The incidence of lung metastasis and malignant transformation were 7.5% (8 out of 107 patients) and 2.7% (3 out of 110 patients), respectively. Repeat recurrence was associated with lung metastasis (p = 0.018).
CONCLUSIONS: Early local recurrence of GCT is a risk factor for repeat recurrence. Repeat recurrence also correlates with lung metastasis. Recurettage with meticulous adjuvant treatment to completely preclude recurrent lesions is a reasonable method for preserving the adjacent joint. However, a continuous careful follow-up is mandatory.

Entities:  

Mesh:

Year:  2011        PMID: 21301899     DOI: 10.1007/s00776-011-0030-x

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  15 in total

1.  The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

Authors:  Wendi O'Connor; Megan Quintana; Scott Smith; Monte Willis; Jordan Renner
Journal:  J Radiol Case Rep       Date:  2014-06-30

2.  Treatment options and prognosis for repeatedly recurrent giant cell tumor of the spine.

Authors:  Yifei Ma; Jialin Li; Jun Pan; Wangjun Yan; Quan Huang; Tielong Liu; Xinghai Yang; Cheng Yang; Wei Xu; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2016-03-17       Impact factor: 3.134

3.  p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.

Authors:  Taketo Okubo; Tsuyoshi Saito; Hiroyuki Mitomi; Tatsuya Takagi; Tomoaki Torigoe; Yoshiyuki Suehara; Kazuo Kaneko; Takashi Yao
Journal:  Virchows Arch       Date:  2013-06-08       Impact factor: 4.064

Review 4.  Secondary Malignancy in Giant Cell Tumor: A Single-Center Study.

Authors:  Min Wook Joo; Yong-Suk Lee; Hong Sik Park; Yang-Guk Chung; Chiyoung Yoon
Journal:  Curr Oncol       Date:  2022-06-02       Impact factor: 3.109

5.  Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.

Authors:  Tetsuya Shinozaki; Kenichi Saito; Tsutomu Kobayashi; Takashi Yanagawa; Kenji Takagishi
Journal:  Open Orthop J       Date:  2012-09-03

Review 6.  Pulmonary metastasis of giant cell tumor of bones.

Authors:  Aikeremujiang Muheremu; Xiaohui Niu
Journal:  World J Surg Oncol       Date:  2014-08-20       Impact factor: 2.754

7.  Risk factors and oncological outcomes of pulmonary metastasis in patients with giant cell tumor of bone.

Authors:  Walid Atef Ebeid; Ismail Tawfeek Badr; Mohamed Kamal Mesregah; Bahaa Zakarya Hasan
Journal:  J Clin Orthop Trauma       Date:  2021-07-09

8.  Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics.

Authors:  Roberto Clayton Lima Oliveira Júnior; Marcelo Glauber da Silva Pereira; Pedro Braga Linhares Garcia; Patrícia Albuquerque Dos Santos; Amanda Dos Santos Cavalcanti; Walter Meohas
Journal:  Rev Bras Ortop       Date:  2016-06-18

9.  Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.

Authors:  Akihiko Takeuchi; Hiroyuki Tsuchiya; Takeshi Ishii; Yoshihiro Nishida; Satoshi Abe; Akihiko Matsumine; Akira Kawai; Kenichi Yoshimura; Takafumi Ueda
Journal:  BMC Musculoskelet Disord       Date:  2016-07-22       Impact factor: 2.362

10.  The Values of Receptor Activator Nuclear Kappa-B Ligand Expression in Stage III Giant Cell Tumor of the Bone.

Authors:  Sabrina Abdul Ghani; Wan Faisham Wan Ismail; Md Salzihan Md Salleh; Sahran Yahaya; Zawawi Muhamad Syahrul Fitri
Journal:  Indian J Orthop       Date:  2018 Jan-Feb       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.